contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

The information provided regarding the Phase 2 study has been quite general so far. In the interview linked by Sijoittaja-alokas above, Vuolanto mentions that they aim to provide more detailed information about the P2 study design “within the next four weeks,” which likely means going deeper into concrete scientific, clinical, and practical details. One could certainly hope for news regarding the financing arrangements as well, but in my opinion, that is fairly unlikely. Edit: And naturally, there will likely be more detailed information about the Invidi collaboration, and the audience will have the opportunity to ask questions.

The company has already reported on both topics, although they could certainly provide endless additional details. Since the finance team is also present, I wonder how it relates to those topics. A press release regarding financing negotiations? It would be strange at this point and perhaps a bad sign for that side of things…

June 2nd: Phase 2 preparation status update to be held                   Inderes              Webcast: Vaiheen 2 valmistelujen tilannekatsaus - Inderes    Herantis Pharma Oyj – Lehdistötiedote 28.5.2026 klo 14.30Webcast: Vaiheen 2 valmistelujen tilannekatsausEspoo, Suomi, 28 Toukokuu 2026: Herantis Pharma Oyj (“Herantis”), kliinisen vaiheen bioteknologi...

Herantis CEO Antti Vuolanto spoke about the company as an investment opportunity at the Investor Day

Here are Antti’s comments regarding the recent news.  Herantis announced on Tuesday that it has entered into a collaboration agreement with the Swiss company Indiv to utilize digital biomarker technology in the upcoming Phase II study of the HER-096 drug candidate. The news is a step forward in study design that aligns with expectations, as we have previously estimated that the company plans to use digital methods for monitoring patient symptoms. The technology can improve the study’s sensitivity to detect potential treatment effects within a relatively short follow-up period.                   Inderes – 20 May 26              Herantis yhteistyöhön Indivin kanssa HER-096:n vaiheen II tutkimuksessa -...    Digitaalinen teknologia voi saada hoitovasteen esiin tulevassa vaiheen II tutkimuksessa.

Not an actual partnership agreement yet, but an interesting collaboration at first glance. This could speed up the timeline for Phase 2 results, reduce the required patient count, and consequently lower the total costs of Phase 2. Edit. It’s confusing that the news had no impact on the share price. After all, the stock has been sliding down for a while now without any negative news.                   Inderes              Herantis Pharman yhteistyö Indivin kanssa voi mahdollistaa varhaisten...    Herantis Pharma Oyj – Lehdistötiedote 19.5.2026 klo 9.00Herantis Pharman yhteistyö Indivin kanssa voi mahdollistaa varhaisten hoitovaikutusten havaitsemisen HER-096:n tulevassa vaiheen 2 tutkimuksessa...

In less than 2 months, we should know the results of the partnership negotiations, which typically last 6–9 months. If the number of stock options is anything to go by, the financial side was certainly not overlooked.

Herantis Pharma

Herantis Pharma Plc – Press release on 28 May 2026 at 2:30 pm EESTWebcast: Update on Phase 2 preparationEspoo, Finland, 28 May 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company...

Herantis Pharma Plc – Press release on 28 May 2026 at 2:30 pm EESTWebcast: Update on Phase 2 preparationEspoo, Finland, 28 May 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that Herantis’ management team will host a webcast on Tuesday 2 June 2026, at 13.00 EEST (12:00 CEST).Herantis CEO Antti Vuolanto, CSO Henri Huttunen and CFO Tone Kvåle will provide an overview of recent corporate developments. Topics to be covered include:<ul><li>Outline of the Phase 2a proof-of-concept efficacy study</li><li>Collaboration with Indivi to integrate its digital biomarker platform into the upcoming Phase 2a proof-of-concept efficacy study of HER-096</li><li>Q&amp;A session</li></ul>Questions can be submitted throughout the webcast event.Attendees are invited to pre-register and join the online event using the following link: <a href="https://herantis.videosync.fi/update-on-phase-2-preparation">https://herantis.videosync.fi/update-on-phase-2-preparation</a>A recording of the webcast will be available on the Company’s website after the event has concluded.For more information, please contact:Herantis Pharma PlcAntti Vuolanto, CEO Tel: +358407517329Tone Kvåle, CFO Tel: +47 915 19576 Email:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a><a href="https://icrinc.com/what-we-do/healthcare/">ICR Healthcare</a> Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage Tel: <a href="tel:+442037095700">+44 20 3709 5700</a> Email: <a href="mailto:herantispharma@icrhealthcare.com">herantispharma@icrhealthcare.com</a>Certified Advisor:UB Corporate Finance LtdTel: +358 9 25 380&nbsp;225Email:&nbsp;<a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Herantis Pharma PlcHerantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.Herantis is listed on the Nasdaq First North Growth Market Finland.Company website:&nbsp;<a href="http://www.herantis.com/">www.herantis.com</a>